Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
The latest announcement is out from AnaptysBio ( (ANAB) ).
On February 12, 2025, AnaptysBio announced significant results from its Phase 2b RENOIR trial for rosnilimab in treating moderate-to-severe rheumatoid arthritis. The trial demonstrated efficacy in key endpoints, including a significant reduction in DAS-28 CRP scores and high CDAI LDA responses, with favorable safety and tolerability profiles, marking a promising advancement in RA treatment.
More about AnaptysBio
AnaptysBio, Inc. is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics.
YTD Price Performance: -7.37%
Average Trading Volume: 675,286
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $395.6M
Find detailed analytics on ANAB stock on TipRanks’ Stock Analysis page.
